Overview
Janpix Inc was launched to advance the discovery and clinical development of highly potent and selective STAT3 & STAT5 protein degraders ("small molecule PROTAC's) based on novel structural insights and chemistry. STAT proteins have been shown to play a vital role not only in tumor cell survival but also in tumor immune evasion. In collaboration with leading academic labs Janpix is advancing several pre-clinical programs targeting different hematological and solid tumors into the clinic.